MARKET

SLDB

SLDB

Solid Bioscience
NASDAQ
6.89
+0.37
+5.67%
Opening 14:58 02/09 EST
OPEN
6.46
PREV CLOSE
6.52
HIGH
6.91
LOW
5.71
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
7.37
52 WEEK LOW
2.410
MARKET CAP
536.80M
P/E (TTM)
-2.7633
1D
5D
1M
3M
1Y
5Y
1D
Solid Biosciences Announces Positive Regulatory Update From Type C Meeting With FDA Supporting Continued Advancement Of SGT-003 As Potential Treatment For Duchenne Muscular Dystrophy
Benzinga · 6h ago
Solid Biosciences Announces FDA Alignment on Phase 3 Trial Design for SGT-003 in Duchenne Muscular Dystrophy
Reuters · 6h ago
Solid Biosciences startet Phase-3-Studie mit SGT-003 gegen Duchenne-Muskeldystrophie
Reuters · 6h ago
SOLID BIOSCIENCES INC - SGT-003 WELL TOLERATED IN PHASE 1/2 TRIAL WITH 36 DOSED AS OF FEB 9
Reuters · 6h ago
Weekly Report: what happened at SLDB last week (0202-0206)?
Weekly Report · 10h ago
Solid Biosciences Leadership Quietly Unloads a Wave of Insider Shares
TipRanks · 2d ago
Solid Biosciences COO David T. Howton Reports Disposal of Common Shares
Reuters · 2d ago
Solid Biosciences CEO Alexander Cumbo Reports Disposal of Common Shares
Reuters · 2d ago
More
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Webull offers Solid Biosciences Inc stock information, including NASDAQ: SLDB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLDB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLDB stock methods without spending real money on the virtual paper trading platform.